Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

K Knop

Showing results (31-40 of 508) with videos related to

Pageof 51
Sort By:
Expert Opinion on Drug Safety|February 3, 2017
Efficacy and safety of fixed-ratio combination of insulin degludec and liraglutide (IDegLira) for the treatment of type 2 diabetesLouise Vedtofte, Filip K Knop, Tina Vilsbøll
Expert Review of Clinical Pharmacology|March 31, 2015
Fixed combination of insulin and a glucagon-like peptide-1 analog for the treatment of type 2 diabetes, exemplified by insulin degludec and liraglutideLouise Vedtofte, Filip K Knop, Tina Vilsbøll
Expert Opinion on Emerging Drugs|September 13, 2011
Emerging GLP-1 receptor agonistsAsger Lund, Filip K Knop, Tina Vilsbøll
Diabetes, Obesity & Metabolism|February 18, 2017
Short-acting glucagon-like peptide-1 receptor agonists as add-on to insulin therapy in type 1 diabetes: A reviewAnders Albèr, Andreas Brønden, Filip K Knop
Ugeskrift for Laeger|October 19, 2012
[Glucagon-like peptide 1 analogues in the treatment of type 2 diabetes mellitus]Mikkel Christensen, Tina Vilsbøll, Filip K Knop
Expert Opinion on Pharmacotherapy|January 14, 2017
Exenatide: pharmacokinetics, clinical use, and future directionsFilip K Knop, Andreas Brønden, Tina Vilsbøll
European Journal of Internal Medicine|April 4, 2014
Glucagon-like peptide-1 receptor agonists for the treatment of type 2 diabetes: differences and similaritiesAsger Lund, Filip K Knop, Tina Vilsbøll
Pancreas|December 17, 2010
First case report associating chronic pancreatitis and Ehlers-Danlos syndromeKatrine B Hansen, Steen Larsen, Filip K Knop
Diabetes Care|April 25, 2015
Pancreatic Amylase and Lipase Plasma Concentrations Are Unaffected by Increments in Endogenous GLP-1 Levels Following Liquid Meal TestsDavid P Sonne, Tina Vilsbøll, Filip K Knop
Nutrition, Metabolism, and Cardiovascular Diseases : NMCD|May 7, 2023
Does glucose lowering restore GIP's effect on insulin secretion?Sten Madsbad, Filip K Knop, Jens J Holst
Pageof 51

Showing results (31-40 of 508) with videos related to

Sort By:
Pageof 51
Expert Opinion on Drug Safety|February 3, 2017
Efficacy and safety of fixed-ratio combination of insulin degludec and liraglutide (IDegLira) for the treatment of type 2 diabetesLouise Vedtofte, Filip K Knop, Tina Vilsbøll
Expert Review of Clinical Pharmacology|March 31, 2015
Fixed combination of insulin and a glucagon-like peptide-1 analog for the treatment of type 2 diabetes, exemplified by insulin degludec and liraglutideLouise Vedtofte, Filip K Knop, Tina Vilsbøll
Expert Opinion on Emerging Drugs|September 13, 2011
Emerging GLP-1 receptor agonistsAsger Lund, Filip K Knop, Tina Vilsbøll
Diabetes, Obesity & Metabolism|February 18, 2017
Short-acting glucagon-like peptide-1 receptor agonists as add-on to insulin therapy in type 1 diabetes: A reviewAnders Albèr, Andreas Brønden, Filip K Knop
Ugeskrift for Laeger|October 19, 2012
[Glucagon-like peptide 1 analogues in the treatment of type 2 diabetes mellitus]Mikkel Christensen, Tina Vilsbøll, Filip K Knop
Expert Opinion on Pharmacotherapy|January 14, 2017
Exenatide: pharmacokinetics, clinical use, and future directionsFilip K Knop, Andreas Brønden, Tina Vilsbøll
European Journal of Internal Medicine|April 4, 2014
Glucagon-like peptide-1 receptor agonists for the treatment of type 2 diabetes: differences and similaritiesAsger Lund, Filip K Knop, Tina Vilsbøll
Pancreas|December 17, 2010
First case report associating chronic pancreatitis and Ehlers-Danlos syndromeKatrine B Hansen, Steen Larsen, Filip K Knop
Diabetes Care|April 25, 2015
Pancreatic Amylase and Lipase Plasma Concentrations Are Unaffected by Increments in Endogenous GLP-1 Levels Following Liquid Meal TestsDavid P Sonne, Tina Vilsbøll, Filip K Knop
Nutrition, Metabolism, and Cardiovascular Diseases : NMCD|May 7, 2023
Does glucose lowering restore GIP's effect on insulin secretion?Sten Madsbad, Filip K Knop, Jens J Holst
Pageof 51